3 active not recruiting, 2 completed, 1 recruiting. 6 Phase 3.
By phase and status
Follow Cystectomy: new trials by email Literature Review of Cystectomy trials Research Report on Cystectomy
Trials (filtered) newest first · largest first
All 6 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt cisplatin based neoadjuvant chemotherapy, Radical cystectomy alone - Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect | Phase 3 | Active not recruiting | 236 | 2026-08-13 | 2026-08-17 |
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC | Phase 3 | Recruiting | 170 | 2026-07-01 | 2026-07-09 |
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | 712 | 2021-08-05 | 2026-06-04 |
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Nivolumab, Radical cystectomy (RC), Bempegaldesleukin - Bladder Cancer, Bladder Tumor | Phase 3 | Completed | 114 | 2020-02-05 | 2024-06-27 |
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin - Urinary Bladder Cancer, Muscle-invasive | Phase 3 | Active not recruiting | 595 | 2019-07-24 | 2026-06-30 |
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) Pembrolizumab, Gemcitabine, Cisplatin - Bladder Cancer | Phase 3 | Completed | 907 | 2019-06-13 | 2026-10-08 |
Conditions studied
Urinary Bladder Neoplasms (5) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Sponsors
Merck Sharp & Dohme LLC (2) · AstraZeneca (1) · Bristol-Myers Squibb (1) · Regina Elena Cancer Institute (1) · Zhiquan Hu (1)
Countries
Italy (5) · Canada (4) · France (4) · Germany (4) · Israel (4) · Mexico (4) · Poland (4) · Spain (4) · United Kingdom (4) · United States (4) · Argentina (3) · Australia (3) · Belgium (3) · Japan (3) · Russia (3)
Top investigators
Giuseppe Simone, MD (1)
Results publications
PMID 34008425, PMID 10470696, PMID 11157016, PMID 12944571, PMID 15273542, PMID 15814643, PMID 16518661, PMID 17116130, PMID 19826360, PMID 21502557, PMID 26579498, PMID 32360052, PMID 33109737, PMID 41193372, PMID 41707170
NIH funding
2018 (3), 2023 (1)